Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: A Bangladesh experience

Bangladesh Medical Research Council Bulletin

Volumn 30, Issue 1, 2004, Pages 1-8

  Pathan, M F ^a   Latif, Z A ^a   Nazneen, N E ^a   Mili, S U ^a  

^a BIRDEM Hospital   (Bangladesh)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BANGLADESH; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC OBESITY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; LOW CALORY DIET; MALE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PATIENT MONITORING; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ADULT; AGED; BANGLADESH; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; HUMANS; LACTONES; LIPASE; MIDDLE AGED; OBESITY; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 4143131023     PISSN: 03779238     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. World Health Organ Tech Rep Ser 894. The problem of overweight & obesity, preventing and managing the global epidemic: Report of a WHO Consultation. WHO. Geneva 2000: 6-10.
2. World Health Organization MONICA Project: Risk factors. Int. J Epidemiol 1989; 18 (Suppl. 1): 46S-55S.
3. Hubert HB et al. Obesity as an independent risk factor for cardiovascular disease: a 26 year follow up of participants in the Framingham Heart Study. Circulation 1983: 67: 968-77.
4. Manson JE et al. A prospective Study of obesity and risk of coronary heart disease in women. N Engl J Med 1990; 322: 882-9.
5. Pi-Sanyer FX. Health implications of obesity. Am J Clin Nutr 1991; 53 (Suppl. 6): 1595S-1603S.
6. Abbott RD et al. Body mass index and thromboembolic stroke in non-smoking men in older middle age: The Honolulu Heart Program. Stroke 1994; 25: 2370-76.
7. Tai TY et al. Association of body build with non-insulin-dependent diabetes mellitus and hypertension among Chinese adult: a 4 year follow up study. Int J Epidemiol 1992; 21: 511-7.
8. Ohlson LO et al. The influence of body fat distribution in the incidence of Diabetes mellitus: 3.5 years follow up of the participants in the study of men born in 1913. Diabetes 1985: 34: 1055-8.
9. Colditz G, Willet W. Rotnitzky A. Manson J. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122: 481-5.
10. Chan JM et al. Obesity, fat distribution and weight gain as a risk factor for clinical diabetes in men. Diabetes Care 1994; 17: 961-9.
11. Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arterioscler Thromb Vasc Biol 1990; 10: 497-511.
12. Le Marchand L, Wilkens LR, Mi MP. Obesity in youth and middle age and risk of colorectal cancer in men. Cancer Causes Control 1992; 3: 349-54.
13. Hunter SJ, Garvey WT. Insulin action and insulin resistance: disease involving defects in insulin receptors, signal transduction, and the glucose transport effector system. Am J Med 1998; 105: 331-45.
14. Olsson T, Vitanen M, Asplund K, Eriksson S, Hagg E. Prognosis after stoke indiabetic patients: A controlled prospective study. Diabetologia 1990; 33: 244-9.
15. DeFronzo RA, Ferrannini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia & atherosclerotic cardiovascular disease. Diabetes Care 1991: 14: 173-94.
16. Davis TM, Millns H. Stratton IM. Holman RR, Turner RC. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med 1999; 159: 1097-110.
17. Meigs JB, Mittleman MA, Nathan DM. Tofler GH, Singer DE, Murphy-Sheehy PM. et al. Hyperinsulinemia, Hyperglycemia, and Impaired. JAMA 2000; 283: 221-8.
18. Goldstein DJ et al. Beneficial health efforts of modest weight loss. Int J Obes Relat Metab Disord 1992; 16: 397-415.
19. Lean MEJ, Powrie JK, Anderson AS. Garthwaite PH. Obesity, weight loss and prognosis in type 2 diabetes. Diabet Med 1990: 7: 228-33.
20. Williamson DF et al. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol 1995: 141: 1128-41.
21. Wing R, Koeske R, Epstein L, Nowalk M, Gooding W, Becker D. Long term effect of modest weight loss in type 2 diabetes patients Arch Intern Med 1987: 147: 1749-53.
22. Obesity in Scotland. Integrating prevention with weight management: A national guideline recommended for use in Scotland Scottish intercollegiate guideline network. Edinburgh, 1996,
23. Hankey CR et al. Weight loss improves established indices of ischemic heart disease risk. Proc Nutr Soc 1995 54 (P 2): 94A.
24. American Diabetes Association Clinical Practice Recommendations 2001. Diabetes Care 2001; 24 (Suppl 1): 1S-133S.
25. Wing RR, Epstein LH, Paternostro-Bayles M, Kriska A, Nowalk MP, Gooding W. Exercise in behavioral weight control program for obese patients with type diabetes. Diabetologia 1988; 31: 902-9.
26. Boule NG, Haddad E, Kenny GP, Wells GA. Sigal RJ. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA 2001; 286: 1218-27.
27. Khan MA, St Peter JV, Breen GA, Hartley GG, Vessey JT. Diabetes disease stage predicts weight loss outcomes with long-term appetite suppressants. Obes Res 2000; 8: 43-8.
28. Paisey RB, Harvey P, Rice S, Belka I, Bower L, Dunn M et al. An intensive weight loss program in established type 2 diabetes and controls: effects on weight and atherosclerosis risk factors at 1 year. Diabet Med 1998; 15: 73-9.
29. Mittendorfer B, Ostlund RJ, Patterson B, Klein S. Orlistat inhibits dietary cholesterol absorption. Obes Res 2001; 9: 599-604.
30. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord 1997; 21 (Suppl. 3): 12S-23S.
31. Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000; 8:49-61.
32. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-42.
33. Drent ML, Van der Veen EA. First clinical studies with orlistat: a short review. Obes Res 1995; 3 (Suppl 4): 623S-5S.
34. Hawkins F, Duran S, Vilardell E et al. Orlistat promotes glycemia control and other cardiovascular risk factors lowering in obese patients with type 2 diabetes: randomized clinical trial (abstract). Diabetologia 2000; 43 (Suppl. 1): 171S.
35. Lemieux S, Prudqhomme D, Bouchard C, Tremblay A, Despres J. A single thresh value of waist girth identifies normal weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr 1996; 64: 685-93.
36. Deerochanaawong C. Effect of treatment with orlistat in overweight or obese Thai patients with type diabetes (abstract). Diabetes 2001; 50 (Suppl. 2): 433.